

## Noise-Induced Hearing Loss: A Preventable Occupational Disease

Nicholas G. Alexiou, MD, MPH, Tom Gladfelter, MD, and Carmelo Saraceno, MD  
Tampa, Florida

**D**R. TOM GLADFELTER (*Assistant Professor, Department of Family Medicine*): Hearing loss is a common problem encountered in the practice of family physicians. We tend to consider hearing loss in a majority of patients to be due to the aging process, but this is not always true. Hearing loss is often due to a variety or combination of causes, which may require multiple disciplinary approaches for the diagnosis and management, particularly for hearing loss suspected to be noise induced and related to employment. Under this circumstance, the patient, the employer, the community, and the law courts are involved in the proper evaluation and disposition of the case in an interrelated fashion. Noise-induced hearing loss is the kind of health problem that the family physician can contribute to preventing in an important way, from acting as advisor to the patient (who is frequently the employee) for his personal health care to acting as advisor to the employer in the administration and supervision of planning a hazard-free work environment. Without full awareness of all possible ramifications and without careful planning, it is possible for physicians to provide less than optimal management of a case and find themselves caught in a legal dispute. In the following discussion, we will focus on noise-induced hearing loss (NIHL) related to occupation or work exposure.

Dr. Alexiou, the Director of the Regional Center for Occupational Safety and Health at the University of South Florida College of Medicine, will provide a briefing on the basics of noise trauma and the requirements of law.

**DR. NICHOLAS ALEXIOU** (*Assistant Professor, Department of Comprehensive Medicine*): Hearing loss is becoming an increasingly important health hazard of concern to family physicians because of the relative increased intensity and duration of worker exposure to noises associated with industrial societies. Although hearing loss can occur from a variety of insults, the noise-induced hearing loss is the matter of current concern.

Acoustic trauma occurs in the wedge-shaped organ of Corti in the cochlea of the ear. This structure, resting on the basilar membrane, has three outer rows and one inner row of hair cells with the tectorial membrane suspended above them. The hair cells have stereocilia projecting toward the tectorial membrane. The energy of sound causes vibration of these cilia; this vibration is then coded into nerve impulses in the acoustic nerve located beneath the hair cells. These hair cells are quite susceptible to the trauma of loud noise. Noise-induced anatomic changes are seen in the cell bodies, which swell and eventually are destroyed.<sup>1-3</sup> Once destroyed, they are lost forever, leading to loss of function. It is known that sound frequencies in the 1,000- to 4,000-Hz range are transmitted best to the cochlea, which partially explains the typical finding of greatest loss of hearing acuity at 4,000 Hz in acoustic trauma.<sup>3</sup>

Since the mid-1800s work-related hearing loss has been recognized by state legislators, who have set limitations to noise exposure. Federal legislation was passed creating the Noise Control Act of 1972. Attempts to publish a standard for noise control and hearing conservation programs for workers' health and safety have long been frustrated by a variety of interest groups. The Occupational Safety and Health Administration (OSHA) estimates that 1 million workers have noise-induced hearing loss in the United States.<sup>4</sup> Recently OSHA issued a final ruling requiring hearing conservation programs in work places.<sup>5</sup> Effective April 7, 1983, the ruling required employers to administer a hearing conservation program when employee noise exposure equaled or exceeded an 8-hour time-weighted average (TWA) sound level of 85 dB measured on the A scale (dBA). This ruling meant that unless engineering or administrative controls were effective, employees would be prohibited from working without protective hearing devices such as earmuffs or earplugs. The concept of the time-weighted average implies that louder noises could be tolerated for shorter exposure times. A scale was developed to guide directors of hearing conservation programs to help control the dose of noise exposure (Table 1). Workers can tolerate up to 80 dBA for 8 hours a day without developing hearing impairment, but when the level of 85 dBA or more is exceeded, increasing num-

From the Department of Comprehensive Medicine, College of Medicine, University of South Florida, Tampa, Florida. Requests for reprints should be addressed to Dr. Tom Gladfelter, Department of Family Practice, The University of Illinois, One Illini Drive, Box 1649, Peoria, IL 61656.

TABLE 1. EQUIVALENT NOISE EXPOSURE OF DIFFERENT SOUND LEVELS AND THEIR DURATIONS

Sound Level (dBA)	Duration in Hours
90	8
92	6
95	4
97	3
100	2
102	1½
105	1
110	½
115	¼ or less

bers of workers will suffer hearing loss.

The law specified that if the sound level cannot be reduced below the 85-dBA level by engineering controls, the employers must monitor the environmental noise level and keep measurements for the record. To protect the hearing of workers, employers must measure workers' baseline hearing acuity with pure tone audiogram against which subsequent audiograms can be compared. Hearing protectors must be provided and workers must be trained in their use. The audiogram should be repeated annually and the records kept permanently. Employers must keep employee work-place noise-exposure records from obtained sound level measurements for two years. If a worker demonstrates a hearing loss when monitored audiometrically, it indicates that the current conservation program is not effective and additional measures need to be taken to prevent further loss of function.

It is now required that the baseline audiogram be conducted within six months of an employee's first exposure at or above the 85-dBA level. Pure tone audiometry should be performed at 500-, 1,000-, 2,000-, 3,000-, 4,000-, and 6,000-Hz testing frequencies by a licensed or certified audiologist, otolaryngologist, qualified physician, or by a technician who is certified by the Council of Accreditation on Occupational Hearing Conservation. It is important to remember before testing that the employee not be exposed to loud noise for at least 14 hours before the baseline audiogram is taken. This precaution is required to reduce the chance of recording a "temporary threshold shift" of the hearing acuity commonly seen after noise exposure. Ideally a baseline audiogram should be conducted for all employees prior to their employment, but the regulation allows the test to be performed as late as six months after employment. One can see a possible problem arising from this policy if high-frequency hearing loss is identified six months after a person has been working in a noisy environment.

I would like to share with you the experience in our own university screening program. Thirty-one university physical plant employees were given baseline audiograms for the first time in the early part of 1983. The results indicated that eight needed otolaryngologi-

cal consultations because of severe or profound hearing loss. Twelve were advised to have a recheck in six months and 11 were considered normal. That means about 65 percent of workers had abnormal test results or results that suggested hearing loss. None of the workers had complained about hearing loss. It is difficult to say what the university's liability is because no pre-employment physical examinations were conducted that included a baseline audiogram for later comparison. The university is likely to be held responsible in two ways: as causing the loss, or as aggravating a preexisting condition. A private physician's audiogram record would be helpful to explain what had occurred. The value of work-place exposure records of noise levels is obvious to protect the employer and the employee's interests. If the exposure records indicate high ambient noise levels, the university will have difficulty avoiding responsibility, especially if it cannot prove that hearing loss existed before this employment.

This issue introduces the role of the family physician. In performing a preplacement or pre-employment physical examination or in presenting ourselves as protectors of patients' health, it is important that we have good baseline information. A routine physical examination seldom includes a pure tone audiogram. Hearing function is usually assessed by striking a tuning fork, whispering words to the patient, or holding a wristwatch to the ear to assess grossly hearing acuity. This type of screening does not give a reliable or valid test. A valid audiogram is the only record that will stand up in court. If the audiometer test results are on the record, then the physician can serve to protect the interests of the patient.

To sum up, work-related hearing loss is a common problem in American society. With the new regulation, family physicians can no longer superficially examine the hearing function in the routine physical examination. They must obtain audiograms as part of their office medical examinations to protect the interests of their patients and to continue providing quality comprehensive care.

**RESIDENT PHYSICIAN:** What audiogram machines are accessible for use in the office setting?

**DR. ALEXIOU:** There are a variety of portable units that can be used for screening purposes. The cost of the machine is minimal, about \$200 to \$300.

**RESIDENT PHYSICIAN:** Are those reliable as screening devices?

**DR. ALEXIOU:** Definitely! But remember, as mentioned earlier, a test is valid only when it is done on patients who have been free from noise exposure for at least 14 hours, when it is administered by qualified personnel on calibrated equipment, and when it takes place in a controlled environment. A soundproof booth is required for diagnostic purposes, but not for a screening procedure. If findings suggest something abnormal using this type of inexpensive testing, it would be appropriate to refer the patient to an otolaryng-

gologist or audiologist for further workup. Referral in this case would mean suspecting a hearing loss of more than 25 decibels at 500, 1,000, or 2,000 Hz or other unusual irregularity.<sup>6</sup>

**RESIDENT PHYSICIAN:** How do we know whether there has been a significant change after a person has been working for some time and whether this is work related?

**DR. ALEXIOU:** A significant change is demonstrated by a change in hearing threshold relative to the baseline audiogram of an average of 10 dB or more at 2,000-, 3,000-, and 4,000-Hz frequencies in either ear, or a 20-dB or more reduction at any frequency. There is an expected annual decrement of hearing acuity that is age related, which must be considered in evaluating a significant change in hearing acuity.<sup>5,7</sup> By the age of 60 years in man, there is about 10-dB average loss in hearing acuity in speech frequencies.

**RESIDENT PHYSICIAN:** If there is a change from the pre-employment and the follow-up audiogram, does the company check the lifestyle of the employee to see whether there are other factors causing the hearing loss?

**DR. ALEXIOU:** No, this is generally not done. The hearing loss is presumed to be work related, particularly if records document that the employee had been working in a 80- to 90-dBA environment or above. In such a case the company is liable, and the potential monetary award can be significant. Prevention is the real goal. An effective noise control program does not have to be expensive, but it should reduce noise levels to a TWA of 85 dBA or less. An inexpensive set of earplugs can attenuate noise levels that could cause damage, would cost about 5¢, and could be worn all day. Remember, the preferred additional control measures are (1) engineering controls to reduce the origin of the noise, (2) employee education programs to improve the awareness of employees of the need to wear protective devices, and (3) enforcement, which is the proper administration of the hearing protection program by supervisors. These are the three E's to remember.

**DR. GLADFELTER:** From the viewpoint of the family physician who conducts periodic or pre-employment physical examinations, the inclusion of an audiogram means additional cost for trained personnel, equipment, a quiet room or a soundproof booth, and the time required to conduct the test. The cost effectiveness of providing testing depends on the sound level exposure experienced by the patient. Audiograms are not routinely necessary for people working all day in a quiet office, but these baseline data are definitely needed for people who are going to work in noisy places, such as factories and construction sites. An inquiry into the occupational history will identify people at risk. It is also important to ask about a history of other symptoms often associated with noise trauma. Difficulty in hearing conversation in noisy places, transient tinnitus, or speech or other

sounds muffled after work are important indicators of possible noise-induced hearing loss.<sup>8</sup> Patients often may not verbalize or volunteer such symptoms during physical examination, yet these are the symptoms we need to identify for an audiogram. Remember, however, that when these symptoms are present, permanent damage may have already occurred.

Next, let me introduce Dr. Saraceno, an otolaryngologist, who will discuss the clinical evaluation of hearing loss.

**DR. CARMELO SARACENO** (*Associate Professor, Department of Otolaryngology*): What Dr. Alexiou has been talking about is becoming increasingly important in industrialized society; we can expect patients coming to us with chief complaints of hearing loss. Now how do we evaluate the complaint and identify those patients with NIHL?

I will limit my efforts to NIHL, presbycusis, otosclerosis, and drug-induced hearing loss in the following discussion. Patients with these disorders are often adults with few or no symptoms, their otoscopic examinations are often normal, and their disorder can be hard to differentiate by history and physical examination alone.

With the exception of otosclerosis, these disorders are due to sensorineural hearing loss with the pathology found in the inner ear—the cochlea and acoustic nerve, where the sound energy is encoded into nervous impulses. If you question patients closely, sensorineural hearing loss usually presents with the symptoms mentioned earlier by Dr. Gladfelter. Patients have difficulty in understanding when in crowded and noisy rooms, and there may be tinnitus. Both symptoms are common in sensorineural hearing loss. In contrast, otosclerosis is a conductive hearing loss, often found in young to middle-aged women. The pathology presents in the middle ear with sclerotic changes in the ossicles leading to a reduction of sound energy transmission to the inner ear. These patients can experience tinnitus, but they often have a lesser problem of hearing conversation in a crowded room; in fact, they may hear better, a phenomenon known as “paracusia willisiana.”<sup>9</sup> It serves as a good indicator of otosclerosis or other conductive hearing losses.

Vertigo is another important symptom to look for, as it is one of the first presenting symptoms of inner-ear pathology. The labyrinth is part of the inner ear. Any etiological factor involving the cochlea will likely involve the labyrinth, and the patient will suffer from vertigo. Meniere's disease is a good example, with its characteristic triad of vertigo, hearing loss, and tinnitus.<sup>10</sup> Vertigo and high-pitched tinnitus are early signs of acoustic neuroma. Both are also frequently present with ototoxicity resulting from medicine or drugs. Seldom found in patients with NIHL and presbycusis, vertigo is important in discriminating Meniere's disease and ototoxicity of drugs from the other causes of sensorineural hearing loss.

*Continued on page 412*

# SINEQUAN® (doxepin HCl)

## BRIEF SUMMARY

### SINEQUAN® (doxepin HCl) Capsules/Oral Concentrate

**Contraindications.** SINEQUAN is contraindicated in individuals who have shown hypersensitivity to the drug. Possibility of cross sensitivity with other dibenzoxepines should be kept in mind.

SINEQUAN is contraindicated in patients with glaucoma or a tendency to urinary retention. These disorders should be ruled out, particularly in older patients.

**Warnings.** The once-a-day dosage regimen of SINEQUAN in patients with intercurrent illness or patients taking other medications should be carefully adjusted. This is especially important in patients receiving other medications with anticholinergic effects.

**Usage in Geriatrics:** The use of SINEQUAN on a once-a-day dosage regimen in geriatric patients should be adjusted carefully based on the patient's condition.

**Usage in Pregnancy:** Reproduction studies have been performed in rats, rabbits, monkeys and dogs and there was no evidence of harm to the animal fetus. The relevance to humans is not known. Since there is no experience in pregnant women who have received this drug, safety in pregnancy has not been established. There are no data with respect to the secretion of the drug in human milk and its effect on the nursing infant.

**Usage in Children:** The use of SINEQUAN in children under 12 years of age is not recommended because safe conditions for its use have not been established.

**MAO Inhibitors:** Serious side effects and even death have been reported following the concomitant use of certain drugs with MAO inhibitors. Therefore, MAO inhibitors should be discontinued at least two weeks prior to the cautious initiation of therapy with SINEQUAN. The exact length of time may vary and is dependent upon the particular MAO inhibitor being used, the length of time it has been administered, and the dosage involved.

**Usage with Alcohol:** It should be borne in mind that alcohol ingestion may increase the danger inherent in any intentional or unintentional SINEQUAN overdosage. This is especially important in patients who may use alcohol excessively.

**Precautions.** Since drowsiness may occur with the use of this drug, patients should be warned of the possibility and cautioned against driving a car or operating dangerous machinery while taking the drug. Patients should also be cautioned that their response to alcohol may be potentiated.

Since suicide is an inherent risk in any depressed patient and may remain so until significant improvement has occurred, patients should be closely supervised during the early course of therapy. Prescriptions should be written for the smallest feasible amount.

Should increased symptoms of psychosis or shift to manic symptomatology occur, it may be necessary to reduce dosage or add a major tranquilizer to the dosage regimen.

**Adverse Reactions. NOTE:** Some of the adverse reactions noted below have not been specifically reported with SINEQUAN use. However, due to the close pharmacological similarities among the tricyclics, the reactions should be considered when prescribing SINEQUAN.

**Anticholinergic Effects:** Dry mouth, blurred vision, constipation, and urinary retention have been reported. If they do not subside with continued therapy, or become severe, it may be necessary to reduce the dosage.

**Central Nervous System Effects:** Drowsiness is the most commonly noticed side effect. This tends to disappear as therapy is continued. Other infrequently reported CNS side effects are confusion, disorientation, hallucinations, numbness, paresthesias, ataxia, and extrapyramidal symptoms and seizures.

**Cardiovascular:** Cardiovascular effects including hypotension and tachycardia have been reported occasionally.

**Allergic:** Skin rash, edema, photosensitization, and pruritus have occasionally occurred.

**Hematologic:** Eosinophilia has been reported in a few patients. There have been occasional reports of bone marrow depression manifesting as agranulocytosis, leukopenia, thrombocytopenia, and purpura.

**Gastrointestinal:** Nausea, vomiting, indigestion, taste disturbances, diarrhea, anorexia, and aphthous stomatitis have been reported. (See anticholinergic effects.)

**Endocrine:** Raised or lowered libido, testicular swelling, gynecomastia in males, enlargement of breasts and galactorrhea in the female, raising or lowering of blood sugar levels, and syndrome of inappropriate antidiuretic hormone have been reported with tricyclic administration.

**Other:** Dizziness, tinnitus, weight gain, sweating, chills, fatigue, weakness, flushing, jaundice, alopecia, and headache have been occasionally observed as adverse effects.

**Withdrawal Symptoms:** The possibility of development of withdrawal symptoms upon abrupt cessation of treatment after prolonged SINEQUAN administration should be borne in mind. These are not indicative of addiction and gradual withdrawal of medication should not cause these symptoms.

**Dosage and Administration.** For most patients with illness of mild to moderate severity, a starting daily dose of 75 mg is recommended. Dosage may subsequently be increased or decreased at appropriate intervals and according to individual response. The usual optimum dose range is 75 mg/day to 150 mg/day.

In more severely ill patients higher doses may be required with subsequent gradual increase to 300 mg/day if necessary. Additional therapeutic effect is rarely to be obtained by exceeding a dose of 300 mg/day.

In patients with very mild symptomatology or emotional symptoms accompanying organic disease a lower dosage may suffice. Some of these patients have been controlled on doses as low as 25-50 mg/day.

The total daily dosage of SINEQUAN may be given on a divided or once-a-day dosage schedule. If the once-a-day schedule is employed the maximum recommended dose is 150 mg/day. This dose may be given at bedtime. **The 150 mg capsule strength is intended for maintenance therapy only and is not recommended for initiation of treatment.**

Anti-anxiety effect is apparent before the antidepressant effect. Optimal antidepressant effect may not be evident for two to three weeks.

## Overdosage.

### A. Signs and Symptoms

1. Mild: Drowsiness, stupor, blurred vision, excessive dryness of mouth.
2. Severe: Respiratory depression, hypotension, coma, convulsions, cardiac arrhythmias and tachycardias.

Also: urinary retention (bladder atony), decreased gastrointestinal motility (paralytic ileus), hyperthermia (or hypothermia), hypertension, dilated pupils, hyperactive reflexes.

### B. Management and Treatment

1. Mild: Observation and supportive therapy is all that is usually necessary.
2. Severe: Medical management of severe SINEQUAN overdosage consists of aggressive supportive therapy. If the patient is conscious, gastric lavage, with appropriate precautions to prevent pulmonary aspiration, should be performed even though SINEQUAN is rapidly absorbed. The use of activated charcoal has been recommended, as has been continuous gastric lavage with saline for 24 hours or more. An adequate airway should be established in comatose patients and assisted ventilation used if necessary. EKG monitoring may be required for several days, since relapse after apparent recovery has been reported. Arrhythmias should be treated with the appropriate antiarrhythmic agent. It has been reported that many of the cardiovascular and CNS symptoms of tricyclic antidepressant poisoning in adults may be reversed by the slow intravenous administration of 1 mg to 3 mg of physostigmine salicylate. Because physostigmine is rapidly metabolized, the dosage should be repeated as required. Convulsions may respond to standard anticonvulsant therapy; however, barbiturates may potentiate any respiratory depression. Dialysis and forced diuresis generally are not of value in the management of overdosage due to high tissue and protein binding of SINEQUAN.

More detailed professional information available on request.

**ROERIG** 

A division of Pfizer Pharmaceuticals  
New York, New York 10017

## NOISE-INDUCED HEARING LOSS

Continued from page 409




Figure 1. An actual audiogram of a 55-year-old asymptomatic man who served as a machinist's mate in the Navy for 20 years

I will mention briefly making a diagnosis based on otoscopic examination. In general, all patients with sensorineural hearing losses, including NIHL, have normal-appearing eardrums.<sup>11</sup> The same is true for otosclerosis, but occasionally by careful inspection it is possible to detect a few cases of otosclerosis by looking at the incus through the semitransparent tympanic membrane for a faint pink blush representing the increased vascularity in the otosclerotic bone (Schwartz's sign). The tuning fork is used in the physical examination for the Rinne and the Weber tests. These tests help locate the site or identify the type of hearing loss, but as Dr. Alexiou has pointed out, they should not be used to detect the degree of hearing loss.

With a pure tone audiogram, the degree of hearing loss can be quantitated for the various frequencies of sound. In otosclerosis, the hearing loss occurs in all frequencies when the sound stimulus is presented by the air. When the sound stimulus is presented to the bony surface of the patient, the hearing is improved, which explains the so-called air-bone gap seen in conductive hearing loss. In sensorineural hearing loss, hearing by air and bone conduction are about equal.

So how do we differentiate accurately the hearing loss of NIHL from that of presbycusis or ototoxicity of drugs? This audiogram shows what you should look for in the case of NIHL (Figure 1). Notice a dip at the 4,000-Hz frequency while the speech frequencies (500 to 2,000 Hz) are normal. The predominant loss of hearing acuity around 4,000 Hz with preservation of 8,000 Hz is typical of NIHL. Later on in the process of disease, when the hearing loss becomes progressively worse, the 4,000-Hz loss will become more pronounced and the lower speech frequencies and higher 8,000-Hz frequencies will also become affected.<sup>12</sup> In presbycusis, the pattern is an increased hearing loss in the higher frequencies, with a greater loss in 8,000-Hz than in 4,000-Hz range. If you see this pattern, then the presumptive diagnosis is presbycusis. To complicate the diagnosis, the audiometric finding of hearing loss

due to ototoxicity of drugs is similar to that of presbycusis. In such cases, we have to rely heavily on the medication history to make the differential diagnosis. The drugs known to cause hearing loss include aminoglycoside antibiotics, furosemide, and salicylates, all of which are familiar to us.<sup>13-14</sup> Fortunately, in most circumstances hearing loss that is due to drugs is reversible. It allows us a chance to withdraw the drug. A repeat audiogram should demonstrate improvement with drug withdrawal. In NIHL and presbycusis, however, the loss is permanent, and there is no change in the audiogram with repeated examinations.

The patient with a history of military service, working with noisy machinery, attending musical gatherings, especially to hear modern rock-and-roll music, or other occupational historical events that exposed him or her to high noise level may have developed hearing difficulty insidiously over the years. If the physical examination shows normal eardrums, and the audiogram has the typical dip at 4,000 Hz in both ears without air-bone gap, then you can generally make a fairly accurate diagnosis of NIHL. But you should raise questions if the hearing loss is unilateral. Since noise affects both ears, the impairment is always bilateral except in certain circumstances when each ear is exposed to different noise levels; firing a rifle is a good example. Once asymmetry is significant, other causes of hearing loss need to be evaluated. A disproportionately impaired ability to understand speech is usually diagnostic of an acoustic nerve pathology rather than cochlear pathology.<sup>13</sup>

Audiometric testing requires thorough cooperation from the patients. When the patient is not cooperative, tympanometry, which simply measures the middle-ear pressure and gives an indication of presence of middle-ear pathology,<sup>11</sup> such as fluid accumulation and otosclerosis, can be used. One part of tympanometry is the acoustic reflex, which tells whether the sensory neural level is grossly abnormal. This acoustic reflex measures the stapedius muscle contraction in the non-test ear when a loud sound is delivered to the ear being tested. If a reflex is recorded, the ear is obviously not totally deaf and the entire neural pathway is probably intact. The last diagnostic test I will mention is called auditory brain-stem response audiometry. It is similar to electroencephalography except that it tracks the brain-stem response to auditory stimuli.<sup>11,15</sup> It is especially valuable for people who complain about hearing loss and their audiometric test is not entirely normal or when legal matters are involved.

Otosclerosis is amenable to treatment by surgical procedures. There is no good treatment for sensorineural hearing loss. The only good treatment for NIHL is prevention by protection of the worker and altering the environment to eliminate the unwanted noise. It is very important, especially for the family physician, to treat any concurrent medical problem such as hypertension and diabetes mellitus, and not take for granted that the hearing loss is associated with

the normal aging process. Aggressive therapy for a concurrent medical problem should at least prevent further deterioration of the hearing function.<sup>16,17</sup> This applies to the treatment of presbycusis as well.

For the patient with a disabling hearing loss, a hearing aid will sometimes provide relief. A patient with a high-frequency loss that has a mild effect on speech frequencies can be helped by a high-frequency gain aid.<sup>18</sup> However, if the patient has severe impairment in discriminating between words with close phonation, the likelihood of benefit from a hearing aid is greatly reduced. Tinnitus, which always accompanies mild to severe NIHL, can be sometimes treated by "tinnitus maskers." In this instance a less annoying noise is introduced to mask the presence of the tinnitus.

As a final reminder, when you have a patient with hearing loss, it is very important to sit down with the family members and explain what it means to not be able to hear. Frequently the family will believe the patient hears only what he wants to hear or may not hear when something is inconvenient. It is important for the physician to tell the family that the audiometric test shows the patient has impaired hearing and the family should be understanding and supportive. Sometimes patient and family can be helped to understand each other by attending speech reading courses for persons with different types of disorders in communications.

**RESIDENT PHYSICIAN:** What level of street noise can result in damage to hearing?

**DR. ALEXIOU:** Eighty decibels and above can result in hearing damage. There is individual variation, and sensitive individuals may be susceptible to damage at 80 decibels, but most of the population will be protected if they experience less than 85 decibels of sound level pressure.<sup>19</sup> For reference purposes, noise measurement in a quiet room will be about 40 dB, conversation at 3 feet will measure 60 dB, a home vacuum cleaner will measure 70 dB, a garbage disposal unit at 3 feet will measure 80 dB, a power lawn mower will measure at the operator's ear 100 dB, and a power saw will measure 110 dB.

**DR. SARACENO:** Generally speaking, the shorter the exposure, the louder the noise has to be to cause temporary or permanent hearing loss. Continuous exposure to noise is worse than intermittent exposure. Middle- or high-frequency noises are more harmful than low-frequency noise.

**RESIDENT PHYSICIAN:** Have you seen hearing loss caused by loud music played on a portable stereo with earphones?

**DR. SARACENO:** I have not seen that yet, but I suspect I may see a few patients in the future. A recent Federal Drug Administration bulletin warned about the use of the cordless telephone, which when placed over the ear while it is still ringing can give up to 135 dB of noise and cause severe damage.<sup>20</sup>

**DR. GLADFELTER:** This has been a productive presentation and discussion. I would like to sum this up by urging family physicians to (1) take an occupa-

tional history, (2) selectively use the audiometer for pre-employment physical examinations for high-risk workers, (3) educate your patients to wear protective devices such as earmuffs or plugs, and (4) participate actively as consultant to the employer to help set up hearing conservation programs that comply with the safety regulations to reduce the possibility of litigation and the number of worker compensation claims. We also have the role of coordinators of all medical disciplines to provide the best service to our patients, should the need arise.

#### References

1. Myers D, Schlosser WD, Wolfson JR, et al: Otologic diagnosis and the treatment of deafness. *Clin Symp* 1970; 22(2):37-43
2. Erlandsson B, Hakanson H, Ivarsson A, et al: Hair cell damage in guinea pig due to different kinds of noise. *Acta Otolaryngol (suppl)* 1980; 367:1-43
3. Melnick W: Noise and hearing loss. In Keith RW (ed): *Audiology for the Physician*. Baltimore, Williams & Wilkins, 1980, pp 213-237
4. Department of Labor, Occupational Safety and Health Administration: Part III. Occupational noise exposure, hearing conservation amendment. *Federal Register* 1981; 46(11):4112
5. Occupational noise exposure, hearing conservation amendment, final rule. *Federal Register* 1983; 48(46):9738-9785
6. Fox MS: Industrial noise exposure and hearing loss. In Ballenger JJ (ed): *Disease of The Nose, Throat, and Ear*, ed 12. Philadelphia, Lee & Febiger, 1977, pp 984-986
7. Glorig A: Compensation for industrial hearing loss: The practice in the United States. In Beagley HA (ed): *Audiology and Audiological Medicine*. Oxford, Oxford University Press, 1981, pp 861-879
8. *Guide for Conservation of Hearing in Noise*. Rochester, Minn, American Academy of Ophthalmology and Otolaryngology, 1973
9. Ballenger JJ: Otosclerosis. In *Disease of The Nose, Throat, and Ear*, ed 12. Philadelphia, Lea & Febiger, 1977, pp 885-891
10. Dickens JRE, Graham SS: Meniere's disease 1978-1982. *Am J Otolaryngol* 1984; 5(2):137-155
11. DeWeese DD, Saunders WH: Evaluation of hearing. In *Textbook of Otolaryngology*, ed 6. St. Louis, CV Mosby, 1982, pp 279-295
12. Ruth RA: Audiometric evaluation of noise induced hearing loss. *Otolaryngol Clin North Am* 1979; 12(3):639-654
13. DeWeese DD, Saunders WH: Hearing loss. In *Textbook of Otolaryngology*, ed 6. St. Louis, CV Mosby, 1982, pp 347-373
14. Fausti SA, Rappaport BZ, Schechter MA, et al: Detection of aminoglycoside ototoxicity by high-frequency auditory evaluation, selected case studies. *Am J Otolaryngol* 1984; 5(3):177-182
15. Gibroux AP, Pratt LW: Brain stem evoked response audiometry. *Ann Otol Rhinol Laryngol* 1983; 92:183-186
16. Rosen S, Plester D, El-Mofty A, et al: Relation of hearing loss to cardiovascular disease. *Trans Am Acad Ophthalmol Otolaryngol* 1964; 68:433-444
17. Axelsson A, Sigroth K, Vertes D: Hearing in Diabetics. *Acta Otolaryngol (suppl)* 1978; 356:1-23
18. Sinclair JC: Design and performance of hearing aids. In Bradford LJ, Hardy WG (eds): *Hearing and Hearing Impairment*. New York, Grune & Stratton, 1979, pp 173-192
19. Ward WD: The concept of susceptibility to hearing loss. *J Occup Med* 1965; 7:595-607
20. Hearing loss with cordless phones. *FDA Drug Bull* 1984; 14(3):26

# ISOPTIN® (verapamil HCl/Knoll)

80 mg and 120 mg scored, film-coated tablets

**Contraindications:** Severe left ventricular dysfunction (see *Warnings*), hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock, sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker), 2nd- or 3rd-degree AV block. **Warnings:** ISOPTIN should be avoided in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30% or moderate to severe symptoms of cardiac failure) and in patients with any degree of ventricular dysfunction if they are receiving a beta blocker. (See *Precautions*.) Patients with milder ventricular dysfunction should, if possible, be controlled with optimum doses of digitalis and/or diuretics before ISOPTIN is used. (Note interactions with digoxin under *Precautions*.) ISOPTIN may occasionally produce hypotension (usually asymptomatic, orthostatic, mild and controlled by decrease in ISOPTIN dose). Elevations of transaminases with and without concomitant elevations in alkaline phosphatase and bilirubin have been reported. Such elevations may disappear even with continued treatment; however, four cases of hepatocellular injury by verapamil have been proven by rechallenge. Periodic monitoring of liver function is prudent during verapamil therapy. Patients with atrial flutter or fibrillation and an accessory AV pathway (e.g. W-P-W or L-G-L syndromes) may develop increased antegrade conduction across the aberrant pathway bypassing the AV node, producing a very rapid ventricular response after receiving ISOPTIN (or digitalis). Treatment is usually D.C.-cardioversion, which has been used safely and effectively after ISOPTIN. Because of verapamil's effect on AV conduction and the SA node, 1° AV block and transient bradycardia may occur. High grade block, however, has been infrequently observed. Marked 1° or progressive 2° or 3° AV block requires a dosage reduction or, rarely, discontinuation and institution of appropriate therapy depending upon the clinical situation. Patients with hypertrophic cardiomyopathy (IHSS) received verapamil in doses up to 720 mg/day. It must be appreciated that this group of patients had a serious disease with a high mortality rate and that most were refractory or intolerant to propranolol. A variety of serious adverse effects were seen in this group of patients including sinus bradycardia, 2° AV block, sinus arrest, pulmonary edema and/or severe hypotension. Most adverse effects responded well to dose reduction and only rarely was verapamil discontinued. **Precautions:** ISOPTIN should be given cautiously to patients with impaired hepatic function (in severe dysfunction use about 30% of the normal dose) or impaired renal function, and patients should be monitored for abnormal prolongation of the PR interval or other signs of excessive pharmacologic effects. Studies in a small number of patients suggest that concomitant use of ISOPTIN and beta blockers may be beneficial in patients with chronic stable angina. Combined therapy can also have adverse effects on cardiac function. Therefore, until further studies are completed, ISOPTIN should be used alone, if possible. If combined therapy is used, close surveillance of vital signs and clinical status should be carried out. Combined therapy with ISOPTIN and propranolol should usually be avoided in patients with AV conduction abnormalities and/or depressed left ventricular function. Chronic ISOPTIN treatment increases serum digoxin levels by 50% to 70% during the first week of therapy, which can result in digitalis toxicity. The digoxin dose should be reduced when ISOPTIN is given, and the patients should be carefully monitored to avoid over- or under-digitalization. ISOPTIN may have an additive effect on lowering blood pressure in patients receiving oral antihypertensive agents. Disopyramide should not be given within 48 hours before or 24 hours after ISOPTIN administration. Until further data are obtained, combined ISOPTIN and quinidine therapy in patients with hypertrophic cardiomyopathy should probably be avoided, since significant hypotension may result. Clinical experience with the concomitant use of ISOPTIN and short- and long-acting nitrates suggest beneficial interaction without undesirable drug interactions. Adequate animal carcinogenicity studies have not been performed. One study in rats did not suggest a tumorigenic potential, and verapamil was not mutagenic in the Ames test. **Pregnancy Category C:** There are no adequate and well-controlled studies in pregnant women. This drug should be used during pregnancy, labor and delivery only if clearly needed. It is not known whether verapamil is excreted in breast milk; therefore, nursing should be discontinued during ISOPTIN use. **Adverse Reactions:** Hypotension (2.9%), peripheral edema (1.7%), AV block: 3rd degree (0.8%), bradycardia: HR < 50/min (1.1%), CHF or pulmonary edema (0.9%), dizziness (3.6%), headache (1.8%), fatigue (1.1%), constipation (6.3%), nausea (1.6%), elevations of liver enzymes have been reported. (See *Warnings*.) The following reactions, reported in less than 0.5%, occurred under circumstances where a causal relationship is not certain: ecchymosis, bruising, gynecomastia, psychotic symptoms, confusion, paresthesia, insomnia, somnolence, equilibrium disorder, blurred vision, syncope, muscle cramp, shakiness, claudication, hair loss, macules, spotty menstruation. **How Supplied:** ISOPTIN (verapamil HCl) is supplied in round, scored, film-coated tablets containing either 80 mg or 120 mg of verapamil hydrochloride and embossed with "ISOPTIN 80" or "ISOPTIN 120" on one side and with "KNOLL" on the reverse side. Revised August, 1984. 2385



**KNOLL PHARMACEUTICAL COMPANY**  
30 NORTH JEFFERSON ROAD, WHIPPANY, NEW JERSEY 07981